Clinical application and progression of monoclonal antibodies targeting HER2 extracellular domain Ⅳ in breast cancer

XU Jiaojiao; TAO Jiani; WANG Xiaojia; CHEN Zhanhong

doi:10.6039/j.issn.1001-0408.2024.05.22

您当前的位置：

首页 >

文章列表页 >

Clinical application and progression of monoclonal antibodies targeting HER2 extracellular domain Ⅳ in breast cancer

更新时间：2024-03-08

- Clinical application and progression of monoclonal antibodies targeting HER2 extracellular domain Ⅳ in breast cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 5, Pages: 635-640(2024)
- 作者机构：
  
  1.浙江中医药大学第二临床医学院，杭州;310053
  2.温州医科大学研究生培养基地（浙江省肿瘤医院），杭州　310022
  3.浙江省肿瘤医院乳腺内科，杭州　310022
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.05.22
  CLC： R979.1;R737.9
- Published：15 March 2024，
  
  Received：05 September 2023，
  
  Revised：22 February 2024，
扫描看全文
徐娇娇,陶佳妮,王晓稼等.靶向HER2胞外结构域Ⅳ的单克隆抗体在乳腺癌中的应用进展 ^Δ[J].中国药房,2024,35(05):635-640.

XU Jiaojiao,TAO Jiani,WANG Xiaojia,et al.Clinical application and progression of monoclonal antibodies targeting HER2 extracellular domain Ⅳ in breast cancer[J].ZHONGGUO YAOFANG,2024,35(05):635-640.
徐娇娇,陶佳妮,王晓稼等.靶向HER2胞外结构域Ⅳ的单克隆抗体在乳腺癌中的应用进展 ^Δ[J].中国药房,2024,35(05):635-640. DOI： 10.6039/j.issn.1001-0408.2024.05.22.

XU Jiaojiao,TAO Jiani,WANG Xiaojia,et al.Clinical application and progression of monoclonal antibodies targeting HER2 extracellular domain Ⅳ in breast cancer[J].ZHONGGUO YAOFANG,2024,35(05):635-640. DOI： 10.6039/j.issn.1001-0408.2024.05.22.

摘要

人表皮生长因子受体2（HER2）阳性乳腺癌侵袭性强且易转移，抗HER2靶向药物的应用能显著改善HER2阳性乳腺癌患者的预后。在已上市的HER2靶向药物中，靶向HER2胞外结构域Ⅳ的大分子单克隆抗体是治疗HER2阳性乳腺癌的基础靶向药物，主要包括曲妥珠单抗、伊尼妥单抗和马吉妥昔单抗。曲妥珠单抗用于乳腺癌全线治疗，循证医学证据充分，实践经验充足且安全性可控；伊尼妥单抗与曲妥珠单抗在HER2阳性转移性乳腺癌和新辅助/辅助治疗中疗效相似，且安全性可控；马吉妥昔单抗聚焦于携带

CD16A-158F

等位基因的患者，是晚期乳腺癌后线治疗的选择。临床上需根据患者具体病情选择最适合的药物。

Abstract

Human epidermal growth factor receptor 2 （HER2）-positive breast cancer is aggressive and prone to metastasis，and the applications of HER2 agents have improved the prognosis of patients with HER2-positive breast cancer. Among the marketed HER2 agents，macromolecular monoclonal antibodies that target the extracellular domain Ⅳ of HER2 were the cornerstone drugs of HER2-positive breast cancer，including trastuzumab，inetetamab，and margetuximab. Trastuzumab is available for the full-line treatment of breast cancer with sufficient proof of evidence-based medicine，sufficient practical experience and controllable safety. Inetetamab and trastuzumab have similar efficacy and controllable safety in HER2-positive metastatic breast cancer and neoadjuvant/adjuvant therapy. Margetuximab focuses on patients carrying the

CD16A-158F

allele，and is an option of posterior line treatment for advanced breast cancer. It is necessary to select the most suitable drugs clinically according to the specific condition of the patient.

关键词

乳腺癌人表皮生长因子受体2阳性细胞外结构域Ⅳ单克隆抗体曲妥珠单抗伊尼妥单抗马吉妥昔单抗

Keywords

human epidermal growth factor receptor 2-positiveextracellular domain Ⅳmonoclonal antibodytrastuzumabinetetamabmargetuximab

references

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

郭心怡，吕青. 2023年《NCCN乳腺癌风险降低指南》解读[J]. 中国胸心血管外科临床杂志，2023，30（6）：787-804.

GUO X Y，LYU Q. Interpretation of NCCN Breast Cancer Risk Reduction Guidelines in 2023 [J] Chin J Clin Thorac Cardiovasc Surg，2023，30 （6）：787-804.

WAKS A G，WINER E P. Breast cancer treatment：a review[J]. JAMA，2019，321（3）：288-300.

JrROSKOSKI R. The ErbB/HER family of protein-tyrosine kinases and cancer[J]. Pharmacol Res，2014，79：34-74.

WANG Z X. ErbB receptors and cancer[J]. Methods Mol Biol，2017，1652：3-35.

CHOONG G M，CULLEN G D，O’SULLIVAN C C. Evolving standards of care and new challenges in the management of HER2-positive breast cancer[J]. CA Cancer J Clin，2020，70（5）：355-374.

JUNTTILA T T，AKITA R W，PARSONS K，et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941[J]. Cancer Cell，2009，15（5）：429-440.

TRIANTAFYLLIDI E，TRIANTAFILLIDIS J K. Syste- matic review on the use of biosimilars of trastuzumab in HER2+ breast cancer[J]. Biomedicines，2022，10（8）：2045.

NIELSEN D L，ANDERSSON M，KAMBY C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors[J]. Cancer Treat Rev，2009，35（2）：121-136.

SLAMON D J，LEYLAND-JONES B，SHAK S，et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2[J]. N Engl J Med，2001，344（11）：783-792.

MARTY M，COGNETTI F，MARANINCHI D，et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment：the M77001 study group[J]. J Clin Oncol，2005，23（19）：4265-4274.

RICHARD S，SELLE F，LOTZ J P，et al. Pertuzumab and trastuzumab：the rationale way to synergy[J]. An Acad Bras Cienc，2016，88（Suppl 1）：565-577.

SWAIN S M，MILES D，KIM S B，et al. Pertuzumab，trastuzumab，and docetaxel for HER2-positive metastatic breast cancer （CLEOPATRA）：end-of-study results from a double-blind，randomised，placebo-controlled，phase 3 study[J]. Lancet Oncol，2020，21（4）：519-530.

XU B H，LI W，ZHANG Q Y，et al. Pertuzumab，trastuzumab，and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer （PUFFIN）：a phase Ⅲ，randomized，double-blind，placebo-controlled study[J]. Breast Cancer Res Treat，2020，182（3）：689-697.

MILES D，CIRUELOS E，SCHNEEWEISS A，et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer，with a multivariable approach to guide prognostication[J]. Ann Oncol，2021，32（10）：1245-1255.

XU B H，YAN M，MA F，et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer （PHOEBE）：a multicentre，open-label，randomised，controlled，phase 3 trial[J]. Lancet Oncol，2021，22（3）：351-360.

MA F，YAN M，LI W，et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer （PHILA）：randomised，double blind，multicentre，phase 3 trial[J]. BMJ，2023，383：e076065.

中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南：2023[M].北京：人民卫生出版社，2023：27，85.

Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for breast cancer diagnosis and treatment of Chinese Society of Clinical Oncology （CSCO）：2023[M]. Beijing：People’s Health Publishing House，2023：27，85.

GIANNI L，EIERMANN W，SEMIGLAZOV V，et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone，in patients with HER2-positive locally advanced breast cancer （the NOAH trial）：a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet，2010，375（9712）：377-384.

GIANNI L，EIERMANN W，SEMIGLAZOV V，et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer （NOAH）：follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet Oncol，2014，15（6）：640-647.

GIANNI L，PIENKOWSKI T，IM Y H，et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced，inflammatory，or early HER2-positive breast cancer （NeoSphere）：a randomised multicentre，open-label，phase 2 trial[J]. Lancet Oncol，2012，13（1）：25-32.

GIANNI L，PIENKOWSKI T，IM Y H，et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced，inflammatory，or early-stage HER2-positive breast cancer （NeoSphere）：a multicentre，open-label，phase 2 randomised trial[J]. Lancet Oncol，2016，17（6）：791-800.

SHAO Z M，PANG D，YANG H J，et al. Efficacy，safety，and tolerability of pertuzumab，trastuzumab，and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia：the PEONY phase 3 randomized clinical trial[J]. JAMA Oncol，2020，6（3）：e193692.

SHAO Z M，PANG D，YANG H J，et al. Abstract PD18-03：final analysis of the phase Ⅲ PEONY trial：long-term efficacy and safety of neoadjuvant-adjuvant pertuzumab or placebo，plus trastuzumab and docetaxel，in patients with HER2-positive early or locally advanced breast cancer[J]. Cancer Res，2023，83（5_Suppl）：PD18-3.

WU J，JIANG Z F，LIU Z Z，et al. Neoadjuvant pyrotinib，trastuzumab，and docetaxel for HER2-positive breast cancer （PHEDRA）：a double-blind，randomized phase 3 trial[J]. BMC Med，2022，20（1）：498.

COSTA R B，KURRA G，GREENBERG L，et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer[J]. Ann Oncol，2010，21（11）：2153-2160.

Early Breast Cancer Trialists’ Collaborative Group （EBCTCG）. Trastuzumab for early-stage，HER2-positive breast cancer：a meta-analysis of 13 864 women in seven randomised trials[J]. Lancet Oncol，2021，22（8）：1139-1150.

CAMERON D，PICCART-GEBHART M J，GELBER R D，et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer：final analysis of the HERceptin adjuvant （HERA） trial[J]. Lancet，2017，389（10075）：1195-1205.

GOLDHIRSCH A，GELBER R D，PICCART-GEBHART M J，et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer （HERA）：an open-label，randomised controlled trial[J]. Lancet，2013，382（9897）：1021-1028.

LOIBL S，GIANNI L. HER2-positive breast cancer[J]. Lancet，2017，389（10087）：2415-2429.

王晓闻，刘培培，吕锋华，等. 抗HER2人源化单克隆抗体药物关键质量属性评价[J]. 中国药学杂志，2015，50（12）：1054-1061.

WANG X W，LIU P P，LYU F H. Evaluation of critical quality attributes of an anti-HER2 humanized monoclonal antibody drug[J]. Chin Pharm J，2015，50（12）：1054-1061.

边莉，徐兵河，邸立军，等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J]. 中华医学杂志，2020，100（30）：2351-2357.

BIAN L，XU B H，DI L J，et al. Phase Ⅲ randomized controlled，multicenter，prospective study of recombinant anti-HER2 humanized monoclonal antibody （Cipterbin） combined with vinorelbine in patients with HER2 positive metastatic breast cancer：the HOPES study[J]. Natl Med J China，2020，100（30）：2351-2357.

WANG T，ZHANG P，DI L J，et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer：a subgroup analysis in the HOPES study[J]. Transl Breast Cancer Res，2022，3：15.

LV H M，YAN M，SUN T，et al. Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer：final results from the phase 2 ICU trial[J]. J Clin Oncol，2023，41（16_Suppl）：1042.

FANG W F，ZHAO Y Y，HUANG Y，et al. Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer （NSCLC）：an open-label，phase Ⅰ b trial[J]. J Clin Oncol，2023，41（16_Suppl）：9105.

CHAI Y，LI Q，LIU J X，et al. Neoadjuvant inetetamab combined with pertuzumab，paclitaxel，and carboplatin （TCbIP） for locally advanced HER2-positive breast cancer：primary analysis of a phase Ⅱ study[J]. J Clin Oncol，2023，41（16_Suppl）：e12597.

NORDSTROM J L，GORLATOV S，ZHANG W J，et al. Anti-tumor activity and toxicokinetics analysis of MGAH22，an anti-HER2 monoclonal antibody with enhanced Fc γ receptor binding properties[J]. Breast Cancer Res，2011，13（6）：R123.

危彤，袁芃. Fc段改造单克隆抗体在肿瘤治疗中的应用[J]. 中国普通外科杂志，2022，31（12）：1569-1577.

WEI T，YUAN P. Application of Fc-modified monoclonal antibodies in cancer therapy[J]. Chin J Gen Surg，2022，31（12）：1569-1577.

RUGO H S，IM S A，CARDOSO F，et al. Efficacy of margetuximab vs. trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer：a phase 3 randomized clinical trial[J]. JAMA Oncol，2021，7（4）：573-584.

RUGO H S，IM S A，CARDOSO F，et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer （SOPHIA）：final overall survival results from a randomized phase 3 trial[J]. J Clin Oncol，2023，41（2）：198-205.

MARKHAM A. Margetuximab：first approval[J]. Drugs，2021，81（5）：599-604.

梅斯医学. 2022CSCO专家说：张清媛教授：乳腺癌诊疗的临床进展[EB/OL].[2023-07-06].https：//medsci.cn/article/show_article.do?id=bd33e4674609https://medsci.cn/article/show_article.do?id=bd33e4674609.

MedSci.2022CSCO experts said：Professor Zhang Qingyuan：clinical progress in diagnosis and treatment of breast cancer[EB/OL].[2023-07-06].https：//medsci.cn/article/show_article.do?id=bd33e4674609https://medsci.cn/article/show_article.do?id=bd33e4674609.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰